Hosted on MSN1h
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains BullishShares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...
Semorinemab is under clinical development by AC Immune and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition ...
ASN-90 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success ...
Dr Karan Rajan, an NHS surgeon and University of Sunderland lecturer, has shared his thoughts on 'menstrual blood-derived ...
Yoma was born Sept. 9, 1941 in Yonkers, NY, daughter of Yoma Elizabeth Hall (nee Woolcock) of Rangoon, Burma (now Yangon, ...
Caregivers in Arizona experience the heavy burden of Alzheimer's, with unpaid care valued at $10.2 billion annually.
Investor's Business Daily on MSN3h
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's AgitationShares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.
Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...
Researchers found that combining cardiovascular disease drug classes, particularly antihypertensives, can reduce risk of dementia.
Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...
Frankl believed that life can be made meaningful in a three-fold way: through what we give (in terms of creative work), from ...
Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback